Drugs / N17350
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07339176 | May 2026 → Jul 2028 expected | head and neck neoplasm, melanoma, non-small cell lung carcinoma, skin squamous cell carcinoma +1 | Onchilles Pharma Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-02-02 | Onchilles Pharma Inc | Regulatory Onchilles Pharma Publishes Landmark ELANE Pathway Study onchillespharma.com ↗
Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for N17350 to initiate first-in-human clinical studies in patients with advanced solid tumors. |
| 2025-11-07 | Onchilles Pharma Inc | Results Onchilles Pharma Publishes Landmark ELANE Pathway Study onchillespharma.com ↗
N17350 demonstrated consistent monotherapy efficacy, immune cell sparing, and durable responses across 30 cancer cell lines and 15 in vivo models, including chemotherapy-resistant cells and immunologically “cold” tumors. |
| 2025-04-25 | Onchilles Pharma Inc | Results Onchilles Pharma Presents New Data at AACR 2025 onchillespharma.com ↗
The results show that N17350 maintains its efficacy across various tumor types and treatment histories. |
| 2024-04-23 | Onchilles Pharma Inc | Results SDBJ: Onchilles Pharma Shares Promising Preclinical Data; New Mechanism Discovered Could Treat Wide Range of Cancers onchillespharma.com ↗
Jeff Clemetson of the San Diego Business Journal talked with Onchilles after the Company’s presenation at AACR 2024 of new preclinical data for N17350 and N17465 demonstrating the potential for potent and tumor-selective treatment (read the release here). |
| 2024-04-09 | Onchilles Pharma Inc | Results Onchilles Pharma Presents at AACR 2024 New Preclinical Data for N17350 and N17465 Demonstrating the Potential for Potent and Tumor-Selective Treatment onchillespharma.com ↗ |
| 2023-11-03 | Onchilles Pharma Inc | Results Onchilles Pharma Presents at SITC 2023 New Preclinical Data for N17350, a Potential Pan-Cancer Therapeutic onchillespharma.com ↗
New data presented at SITC 2023 includes evidence of N17350’s ability to regress tumor growth in a human xenograft model of patient-derived ovarian cancer cell lines as well as colon, lung, and prostate cancers. |
| 2023-04-19 | Onchilles Pharma Inc | Results Onchilles Pharma Presents at AACR 2023 New Preclinical Data on N17350, a First-in-Class Immuno-Oncology Drug Candidate with Broad, Potent, and Direct Tumor Killing Activity onchillespharma.com ↗
The data demonstrate N17350, as a monotherapy or in combination with checkpoint inhibitors, abrogates tumor growth, induces a robust immune signature with the potential to establish durable remission, and demonstrates no acquired resistance. |
All press releases naming this drug 12 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N17350 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07339176 ↗ |
| Modality | Protein / enzyme biologic | “recombinant mutant porcine pancreatic elastase (PPE)” NCT07339176 ↗ |
| Route | Other | “N17350 injected into accessible tumor lesions” NCT07339176 ↗ |
| Target | ELANE | “target the neutrophil elastase (ELANE) pathway” NCT07339176 ↗ |